Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Asset Writedowns and Impairment (2017 - 2023)

Amicus Therapeutics' Asset Writedowns and Impairment history spans 7 years, with the latest figure at $367000.0 for Q4 2023.

  • For the quarter ending Q4 2023, Asset Writedowns and Impairment fell 59.49% year-over-year to $367000.0, compared with a TTM value of $1.5 million through Dec 2023, down 80.05%, and an annual FY2025 reading of $1.7 million, down 81.52% over the prior year.
  • Asset Writedowns and Impairment for Q4 2023 was $367000.0 at Amicus Therapeutics, down from $1.1 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $6.6 million in Q1 2022, with the low at $367000.0 in Q4 2023.